IL15 and neoplasm: When IL-15 anti–programmed cell death ligand 1 (PD-L1) and anti–cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibodies were used together in mouse tumor models, the latter were able to survive for a longer time [15].